An Electrochemiluminescent Platform for Living Cell Oxygen Metabolism Monitoring

A novel mitochondria-targetable NIR fluorescent probe for monitoring intracellular hypobromous acid levels

The development of ultrasensitive in situ detection techniques for monitoring hypobromous acid (HBrO) levels in the biological systems is of great significance to reveal its complex pathological and physiological effects. A simple mitochondria-targetable hydrazine-based near-infrared (NIR) fluorescent probe (Mito-NIR) for detecting HBrO in the mitochondria of live cells is presented in this paper. Probe Mito-NIR displays the ultrafast (< 5 s) response for HBrO. It can detect HBrO with high sensitivity. Additionally, it shows high selectivity towards HBrO over other biologically important substances. Finally, it can monitor the changes of endogenous/exogenous HBrO levels in the mitochondria of live cells. A simple mitochondria-targetable NIR fluorescent probe with picomolar sensitivity for HBrO was developed to specifically track mitochondrial HBrO.

Applications of graphene-based electrochemical and optical biosensors in early detection of cancer biomarkers

Graphene is a one-atom-thick carbon compound, which holds promises for detecting cancer biomarkers along with its derivatives. The atom-wide graphene layer is ideal for cancer biomarker detection due to its unique physicochemical properties like increased electrical and thermal conductivity, optical transparency, and enhanced chemical and mechanical strength. The scientific aim of any biosensor is to create a smaller and portable point of care device for easy and early cancer detection; graphene is able to live up to that. Apart from tumour detection, graphene-based biosensors can diagnose many diseases, their biomarkers, and pathogens. Many existing remarkable pieces of research have proven the candidacy of nanoparticles in most cancer biomarkers detection. This article discusses the effectiveness of graphene-based biosensors in different cancer biomarker detection. This article provides a detailed review of graphene and its derivatives that can be used to detect cancer biomarkers with high specificity, sensitivity, and selectivity. We have highlighted the synthesis procedures of graphene and its products and also discussed their significant properties. Furthermore, we provided a detailed overview of the recent studies on cancer biomarker detection using graphene-based biosensors. The different paths to create and modify graphene surfaces for sensory applications have also been highlighted in each section. Finally, we concluded the review by discussing the existing challenges of these biosensors and also highlighted the steps that can be taken to overcome them.

A Non-Enzymatic Sensor Based on Trimetallic Nanoalloy with Poly (Diallyldimethylammonium Chloride)-Capped Reduced Graphene Oxide for Dynamic Monitoring Hydrogen Peroxide Production by Cancerous Cells

Catching cancer at an early stage is necessary to make it easier to treat and to save people's lives rather than just extending them. Reactive oxygen species (ROS) have sparked a huge interest owing to their vital role in various biological processes, especially in tumorigenesis, thus leading to the potential of ROS as prognostic biomarkers for cancer. Herein, a non-enzymatic biosensor for the dynamic monitoring of intracellular hydrogen peroxide (H2O2), the most important ROS, via an effective electrode composed of poly (diallyldimethylammonium chloride) (PDDA)-capped reduced graphene oxide (RGO) nanosheets with high loading trimetallic AuPtAg nanoalloy, is proposed. The designed biosensor was able to measure H2O2 released from different cancerous cells promptly and precisely owing to the impressive conductivity of RGO and PDDA and the excellent synergistic effect of the ternary alloy in boosting the electrocatalytic activity. Built upon the peroxidase-like activity of the nanoalloy, the developed sensor exhibited distinguished electrochemical performance, resulting in a low detection limit of 1.2 nM and a wide linear range from 0.05 μM to 5.5 mM. Our approach offers a significant contribution toward the further elucidation of the role of ROS in carcinogenesis and the effective screening of cancer at an early stage.